ADC Therapeutics SA ADCT
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in ADC Therapeutics SA's annual report to the U.S. Securities and Exchange Commission, filed 10 March 2026. Every sentence was checked against that document before publication.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Not applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on equity has no reading this year — return on capital employed, just below, still does: -49%.
The 4-year record
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.2 |
| Operating income $B | −0.1 | −0.1 | −0.2 | −0.1 |
| EBITDA $B | −0.1 | −0.1 | −0.2 | −0.1 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.2 | −0.2 | −0.2 |
| Free cash flow $B | −0.1 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | −1.12 | −1.62 | −2.94 | −2.01 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — |
| ROE % | — | — | — | −134.6 |
| Shares out B | 0.13 | 0.10 | 0.08 | 0.08 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 4 of the 4 fiscal years we could check. 30 checks were skipped: the balance sheet is not tagged before 2022. 15 checks were skipped: EPS is not tagged before 2022. 15 checks were skipped: revenue is not tagged before 2022.